메뉴 건너뛰기
Critical Care Medicine
Volumn 35, Issue 3, 2007, Pages 994-995
Early goal-directed therapy of septic shock: We honestly remain skeptical [22]
Author keywords

[No Author keywords available]
Indexed keywords

BLOOD TRANSFUSION; DISEASE SEVERITY; EARLY INTERVENTION; EMERGENCY WARD; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; LETTER; MORTALITY; PRIORITY JOURNAL; RESUSCITATION; SEPSIS; SEPTIC SHOCK; SURVIVAL;
EID: 33947161625     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000257481.37623.3B     Document Type: Letter
Times cited : (33)
References (8)
  • 1
    • 33750237410 scopus 로고    scopus 로고
    • Before-after study of a standardized hospital order set for the management of septic shock
    • Micek ST, Roubinian N, Heuring T, et al: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707-2713
    • (2006) Crit Care Med , vol.34 , pp. 2707-2713
    • Micek, S.T.1    Roubinian, N.2    Heuring, T.3
  • 2
    • 33750274056 scopus 로고    scopus 로고
    • Early goal-directed therapy of septic shock in the emergency room: Who could honestly remain skeptical?
    • Carlet J: Early goal-directed therapy of septic shock in the emergency room: Who could honestly remain skeptical? Crit Care Med 2006; 34:2842-2843
    • (2006) Crit Care Med , vol.34 , pp. 2842-2843
    • Carlet, J.1
  • 3
    • 0035829842 scopus 로고    scopus 로고
    • Early goal-directed therapy in the treatment of severe sepsis and septic shock
    • Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
    • (2001) N Engl J Med , vol.345 , pp. 1368-1377
    • Rivers, E.1    Nguyen, B.2    Havstad, S.3
  • 4
    • 0038690407 scopus 로고    scopus 로고
    • Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial
    • Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
    • (2003) JAMA , vol.290 , pp. 238-247
    • Abraham, E.1    Reinhart, K.2    Opal, S.3
  • 5
    • 0035826096 scopus 로고    scopus 로고
    • Efficacy and safety of recombinant human activated protein C for severe sepsis
    • Bernard GR, Vincent J-L, Laterre P-F, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
    • (2001) N Engl J Med , vol.344 , pp. 699-709
    • Bernard, G.R.1    Vincent, J.-L.2    Laterre, P.-F.3
  • 6
    • 0032433470 scopus 로고    scopus 로고
    • Has the mortality of septic shock changed with time
    • Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time. Crit Care Med 1998; 26:2078-2086
    • (1998) Crit Care Med , vol.26 , pp. 2078-2086
    • Friedman, G.1    Silva, E.2    Vincent, J.L.3
  • 7
    • 1942500845 scopus 로고    scopus 로고
    • EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units
    • Brun-Buisson C, Meshaka P, Pinton P, et al: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
    • (2004) Intensive Care Med , vol.30 , pp. 580-588
    • Brun-Buisson, C.1    Meshaka, P.2    Pinton, P.3
  • 8
    • 0343360868 scopus 로고    scopus 로고
    • A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
    • Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
    • (1999) N Engl J Med , vol.340 , pp. 409-417
    • Hebert, P.C.1    Wells, G.2    Blajchman, M.A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.